Roche (OTCMKTS:RHHBY) Sets New 1-Year High – Time to Buy?

Roche Holding AG (OTCMKTS:RHHBY)’s share price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $44.31 and last traded at $44.24, with a volume of 7251897 shares traded. The stock had previously closed at $43.26.

Wall Street Analyst Weigh In

RHHBY has been the subject of several recent analyst reports. Sanford C. Bernstein upgraded shares of Roche to a “strong-buy” rating in a research report on Thursday, January 30th. UBS Group upgraded shares of Roche from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, Morgan Stanley assumed coverage on shares of Roche in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Roche currently has a consensus rating of “Moderate Buy”.

Roche Trading Up 2.3 %

The business’s 50 day moving average price is $39.81 and its 200-day moving average price is $38.51. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.86.

Institutional Investors Weigh In On Roche

Institutional investors and hedge funds have recently made changes to their positions in the stock. Canopy Partners LLC grew its holdings in shares of Roche by 4.6% in the third quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock valued at $310,000 after purchasing an additional 344 shares in the last quarter. Brooklyn Investment Group acquired a new position in shares of Roche in the third quarter valued at approximately $40,000. IHT Wealth Management LLC acquired a new position in shares of Roche in the third quarter valued at approximately $236,000. Bard Financial Services Inc. grew its holdings in shares of Roche by 156.8% in the third quarter. Bard Financial Services Inc. now owns 80,500 shares of the company’s stock valued at $3,216,000 after purchasing an additional 49,150 shares in the last quarter. Finally, Confluence Investment Management LLC grew its holdings in shares of Roche by 26.3% in the fourth quarter. Confluence Investment Management LLC now owns 13,981 shares of the company’s stock valued at $488,000 after purchasing an additional 2,910 shares in the last quarter.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.